334 related articles for article (PubMed ID: 29258644)
1. A benefit-risk analysis of rotavirus vaccination, France, 2015.
Lamrani A; Tubert-Bitter P; Hill C; Escolano S
Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258644
[TBL] [Abstract][Full Text] [Related]
2. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018.
Escolano S; Mueller JE; Tubert-Bitter P
Euro Surveill; 2020 Aug; 25(33):. PubMed ID: 32820718
[TBL] [Abstract][Full Text] [Related]
3. Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
Ledent E; Arlegui H; Buyse H; Basile P; Karkada N; Praet N; Nachbaur G
BioDrugs; 2018 Apr; 32(2):139-152. PubMed ID: 29589230
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
[TBL] [Abstract][Full Text] [Related]
5. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
[TBL] [Abstract][Full Text] [Related]
6. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
[TBL] [Abstract][Full Text] [Related]
7. Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.
Ledent E; Lieftucht A; Buyse H; Sugiyama K; Mckenna M; Holl K
Drug Saf; 2016 Mar; 39(3):219-30. PubMed ID: 26748506
[TBL] [Abstract][Full Text] [Related]
8. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of rotavirus gastroenteritis and need of high rotavirus vaccine coverage with early completion of vaccination schedule for protection against rotavirus diarrhea in India: A narrative review.
Raju B; Parikh RP; Vetter VV; Kolhapure S
Indian J Public Health; 2019; 63(3):243-250. PubMed ID: 31552856
[TBL] [Abstract][Full Text] [Related]
10. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
Arlegui H; Nachbaur G; Praet N; Bégaud B; Caro JJ
Clin Ther; 2020 Oct; 42(10):1983-1991.e2. PubMed ID: 32988633
[TBL] [Abstract][Full Text] [Related]
11. Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines.
Uhlig U; Kostev K; Schuster V; Koletzko S; Uhlig HH
Pediatr Infect Dis J; 2014 Nov; 33(11):e299-304. PubMed ID: 24911897
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of an ideal rotavirus vaccine.
Reisinger KS; Block SL
Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
[TBL] [Abstract][Full Text] [Related]
13. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
[TBL] [Abstract][Full Text] [Related]
14. Analysis of hospitalizations due to intussusception in Sicily in the pre-rotavirus vaccination era (2003-2012).
Costantino C; Restivo V; Cuccia M; Furnari R; Amodio E; Vitale F
Ital J Pediatr; 2015 Aug; 41():52. PubMed ID: 26232152
[TBL] [Abstract][Full Text] [Related]
15. Intussusception following rotavirus vaccination: an updated review of the available evidence.
Rha B; Tate JE; Weintraub E; Haber P; Yen C; Patel M; Cortese MM; DeStefano F; Parashar UD
Expert Rev Vaccines; 2014 Nov; 13(11):1339-48. PubMed ID: 25066368
[TBL] [Abstract][Full Text] [Related]
16. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.
Carlin JB; Macartney KK; Lee KJ; Quinn HE; Buttery J; Lopert R; Bines J; McIntyre PB
Clin Infect Dis; 2013 Nov; 57(10):1427-34. PubMed ID: 23964090
[TBL] [Abstract][Full Text] [Related]
17. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C
Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466
[TBL] [Abstract][Full Text] [Related]
18. Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies.
Sun ZW; Fu Y; Lu HL; Yang RX; Goyal H; Jiang Y; Xu HG
JAMA Pediatr; 2021 Jul; 175(7):e210347. PubMed ID: 33970192
[TBL] [Abstract][Full Text] [Related]
19. Rotavirus vaccination in Brazil: effectiveness and health impact seven years post-introduction.
Linhares AC; Justino MC
Expert Rev Vaccines; 2014 Jan; 13(1):43-57. PubMed ID: 24308577
[TBL] [Abstract][Full Text] [Related]
20. Rotavirus vaccines: a story of success.
Kollaritsch H; Kundi M; Giaquinto C; Paulke-Korinek M
Clin Microbiol Infect; 2015 Aug; 21(8):735-43. PubMed ID: 25680314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
